Sensipar Hypocalcemia Studies Are Key To Expanded Indication, Amgen Says
Executive Summary
Long-term hypocalcemia safety studies will be necessary before Amgen gains approval of an expanded indication for the chronic kidney disease agent Sensipar
You may also be interested in...
Abbott Will Grow Zemplar Sales With Oral Formulation, Pre-dialysis Use
Abbott expects that an oral formulation of Zemplar (paricalcitol) could increase the chronic kidney disease agent's market ten-fold
Abbott Will Grow Zemplar Sales With Oral Formulation, Pre-dialysis Use
Abbott expects that an oral formulation of Zemplar (paricalcitol) could increase the chronic kidney disease agent's market ten-fold
Sensipar Is $8.10 Per 30 Mg; “Fair Price” For “Major Advance,” Amgen Says
Amgen's Sensipar (cinacalcet) will cost $8.10 per 30 mg tablet, Amgen says